Erratum to “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib” [Lung Cancer, 108 (June 2017) 228–231]

The publisher regrets the title was published with an error. This has now been corrected.

Source: Lung Cancer - August 21, 2019 Category: Cancer & Oncology Authors: Sai-Hong Ignatius Ou, Jean Cui, Alexa B. Schrock, Michael E. Goldberg, Viola W. Zhu, Lee Albacker, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali Tags: Erratum Source Type: research